Supply Chain | April 27, 2022
Takeda awarded for Supply Chain and Pharma 4 at ISPE awards
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Subscribe To Our Newsletter & Stay Updated
